C1-esterase inhibitor - BioGeniusAlternative Names: Human plasma derived C1-esterase inhibitor; Human purified derived C1-esterase inhibitor
Latest Information Update: 26 Nov 2015
At a glance
- Originator BioGenius
- Mechanism of Action Complement C1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Sepsis; Septic shock
Most Recent Events
- 26 Nov 2015 BioGenius' C1-esterase inhibitor is still at the phase III stage of development in Russia